背景:血小板活化引发的血栓形成在心脑血管疾病的发病机制中起着至关重要的作用。
目的:本研究旨在寻找心血管疾病的血小板联合生物标志物,并探讨刀豆蛋白A(ConA)作为新的药理靶点作用于血小板的可能性。
方法:将高通量技术和生物信息学分析相结合,利用GEO数据库筛选获得各组急性心肌梗死(AMI)和镰状细胞病(SCD)的微阵列芯片基因表达谱。使用R语言语言语言包获得差异表达基因(DEGs)。GO,KEGG,和其他数据库被用来执行DEG功能的富集分析,通路,等。使用STRING数据库和Cytoscape软件构建PPI网络,用MCC算法获得两组DEGs的200个核心基因。通过构建交叉区域筛选来确认核心目标。一种分子探针,康纳,与上述核心靶标分子对接在Zdock上,HEX,和3D-DOCK服务器。
结果:我们发现了六个核心标记,CD34,SOCS2,ABL1,MTOR,VEGFA,和SMURF1,它们同时与两种疾病有关,对接效果表明,VEGFA表现最好。
结论:VEGFA最有可能通过与ConA结合来降低其表达,这可能会影响血小板活化过程中PI3K/Akt信号通路的下游调控。其他一些核心靶标也有机会与ConA相互作用以影响血小板激活的血栓形成并引发心血管事件的变化。
Thrombosis triggered by platelet activation plays a vital role in the pathogenesis of cardiovascular and cerebrovascular diseases.
This study aims to find platelet combined biomarkers for cardiovascular diseases and investigate the possibility of Concanavalin A (ConA) acting on platelets as a new pharmacological target.
High-throughput Technology and bioinformatics analysis were combined and groups of microarray chip gene expression profiles for acute myocardial infarction (AMI) and sickle cell disease (SCD) were obtained using GEO database screening. R language limma package was used to obtain differentially expressed genes (DEGs). GO, KEGG, and other databases were utilized to perform the enrichment analysis of DEGs\' functions, pathways, etc. PPI network was constructed using STRING database and Cytoscape software, and MCC algorithm was used to obtain the 200 core genes of the two groups of DEGs. Core targets were confirmed by constructing an intersection area screening. A type of molecular probe, ConA, was molecularly docked with the above core targets on the Zdock, HEX, and 3D-DOCK servers.
We found six core markers, CD34, SOCS2, ABL1, MTOR, VEGFA, and SMURF1, which were simultaneously related to both diseases, and the docking effect showed that VEGFA is the best-performing.
VEGFA is most likely to reduce its expression by binding to ConA, which could affect the downstream regulation of the PI3K/Akt signaling pathway during platelet activation. Some other core targets also have the opportunity to interact with ConA to affect platelet-activated thrombosis and trigger changes in cardiovascular events.